Formulations:
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection
Indications:
- Other specified malignant neoplasms of the ovary
- Germ cell tumour of testis
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Osteosarcoma of bone and articular cartilage of unspecified sites
- Rhabdomyosarcoma primary site
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Burkitt lymphoma including Burkitt leukaemia
- Malignant neoplasms of kidney, except renal pelvis
- Anaplastic large cell lymphoma, ALK-negative
- Anaplastic large cell lymphoma, ALK-positive
Source: EML workbook import
Product metadata will be available once the catalog entry is complete.
Formulations:
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection
Indications:
- Other specified malignant neoplasms of the ovary
- Germ cell tumour of testis
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Osteosarcoma of bone and articular cartilage of unspecified sites
- Rhabdomyosarcoma primary site
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Burkitt lymphoma including Burkitt leukaemia
- Malignant neoplasms of kidney, except renal pelvis
- Anaplastic large cell lymphoma, ALK-negative
- Anaplastic large cell lymphoma, ALK-positive
Source: EML workbook import